At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 136 enrolled
Drug / intervention
Exparel +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy of the Liposomal Bupivacaine for Postoperative Pain Control in Urologic Procedures
In Brief
A Phase 4 clinical trial evaluating Exparel and Marcaine for Urinary Tract Diseases. Completed, enrolled 136 participants across 1 site.
Detailed Summary
A prospective, randomized controlled study to determine the efficacy of liposomal bupivacaine given by local injection at all the wound sites in patients undergoing urologic surgeries.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUrinary Tract Diseases
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
2017201820192020202120222023202420252026
First PostedJun 2016
Enrollment StartJul 2016
Primary CompletionMay 2022
TodayJul 2026
First PostedJun 20, 2016
Enrollment StartJul 11, 2016
Primary CompletionMay 9, 2022
TodayJul 2, 2026
Enrollment to primary: 5.8 yearsPosted 10.0 years ago
Interventions
Expareldrug
This group will receive intraoperative local Liposomal Bupivacaine injection at the surgical site.
Marcainedrug
This group will receive intraoperative Bupivacaine HCl injection at the surgical site.